Abstracts tagged "Renal"

Abstract Number: 0544 • ACR Convergence 2023
Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis
Ranjan Gupta¹, Amita Aggarwal², Avinash Jain³, Liza Rajasekhar⁴, Chengappa Kavadichanda⁵, Vineeta Shobha⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Bidyut Das⁹ and Manish Rathi¹⁰, ¹All India Institute of Medical Sciences, New Delhi, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ³SMS Medical College, Lucknow, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁶St. John's National Academy of Health Science, Bangalore, India, ⁷Christian Medical College, Vellore, India, ⁸Govt of West Bengal, Kolkata, India, ⁹SCB medical college, Cuttack, India, ¹⁰Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Anti-dsDNA antibodies (ADA) are traditionally measured by ELISA and are associated with Lupus nephritis (LN). Testing by immunoline assay (IL) provides additional information on…
Abstract Number: 1519 • ACR Convergence 2023
Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis
Malcolm MacKenzie¹, Harry Atkins² and Nancy Maltez¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Rapidly progressive diffuse systemic sclerosis (SSc) is a devastating autoimmune disease with high morbidity and mortality. Autologous hematopoietic stem cell transplantation (AHSCT) is recognized…
Abstract Number: 0601 • ACR Convergence 2023
Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue
Simon Zhou¹, Krishani Kumari Rajanayake², Miao He², Bo Wen², Ankhbayar Lkhagva², Ernie Yap³, Duxin Sun², Jennifer Cross¹, Kory Engelke¹ and Robert B. Huizinga⁴, ¹Aurinia Pharmaceuticals Inc., Rockford, MD, ²University of Michigan, Ann Arbor, MI, ³Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁴Reformation Consulting Services, North Saanich, BC, Canada
Background/Purpose: The calcineurin inhibitors (CNI) cyclosporine (CSA) and tacrolimus (TAC) were revolutionary when first introduced for solid organ transplant. Voclosporin (VCS), a novel CNI, is…
Abstract Number: 1523 • ACR Convergence 2023
The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis
Muruganandam Maheswari, Eyerusalem Akpan, Matthew Mcelwee, Meredith Keller, Angie Ariza - Hutchinson, Rosemina Patel, Wilmer Sibbitt, Frank O'Sullivan, Sharon nunez, N. Suzanne Emil and Roderick Fields, University of New Mexico, Albuquerque, NM
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but a life-threatening complication of systemic sclerosis (SSc), affecting 2-15% of patients with SSc. SRC has been…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 1083 • ACR Convergence 2022
Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide
Dario Roccatello¹, Savino Sciascia², Stefano Murgia¹, Giacomo Quattrocchio¹, Michela Ferro¹, Emanuele De Simone¹, Carla Naretto¹, Antonella Barreca¹, Daniela Rossi¹, Vittorio Modena¹ and Roberta Fenoglio¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitis associated with antineutrophil cytoplasm antibodies (AAV) in…
Abstract Number: 1089 • ACR Convergence 2022
Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Yeo jin lee¹, Soo Min Ahn², Ji Seon Oh³, Yong Gil Kim², Chang Keun Lee², Bin Yoo² and Seokchan Hong², ¹Asan medical center, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease that can involve various organs systematically. Kidney involvement, one of the major manifestations of AAV,…
Abstract Number: 1360 • ACR Convergence 2022
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Alberta Children's Hospital, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 1483 • ACR Convergence 2022
Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort
Rajat Kharbanda, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Systemic lupus erythematosus (SLE) commonly involve kidney, with increase in creatinine due to lupus related or unrelated cause. Renal biopsy remains gold standard in…
Abstract Number: 1530 • ACR Convergence 2022
Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality
Aditi Patel¹, Chao Zhang¹ and Soumya Chatterjee², ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication in patients with systemic sclerosis (SSc), characterized by accelerated hypertension and acute kidney injury. ACE inhibitors…
Abstract Number: 1636 • ACR Convergence 2022
Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort
Murray Urowitz¹, Mary E. Georgiou², Jiandong Su³, Anne MacKinnon³, Yulia Green⁴, Kerry Gairy², Roger A Levy⁵ and Patricia C. Juliao⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, ⁴GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁶GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA
Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials…
Abstract Number: 0144 • ACR Convergence 2022
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
Guy Katz¹, Amelia S. Cogan¹, Grace McMahon¹, Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹, John Atkinson², Alfred Kim² and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Washington University School of Medicine, St. Louis, MO, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
Abstract Number: 1694 • ACR Convergence 2022
Skin Exposure to UV Light Triggers Podocyte and Distal Tubular Injury, in the Presence of CD177+ Neutrophil Cell Cluster
Angelique Cortez¹, Lindsay Mendyka¹, Fred Kolling² and Sladjana Skopelja-Gardner¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Sensitivity to ultraviolet (UV) light affects ~ 80% of systemic lupus erythematosus (SLE) patients. UV light exposure of lupus skin leads to local and…
Abstract Number: 0344 • ACR Convergence 2022
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie Bartels⁴, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet…
Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abdul Abdellatif¹, Yan Xin², Jason Chamberlain³, Lin Zhao², Katya Cherny³, Brad Marder⁴, John D Scandling⁵ and kenneth saag⁶, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics, Deerfield, IL, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO, ⁵Stanford University School of Medicine, Division of Nephrology, Palo Alto, CA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].